Effects of Semaglutide in HIV-Associated Lipohypertrophy

NCT04019197 on ClinicalTrials.gov · last registry update 2026-05-04

Closed to new participants; the 108 already enrolled are still being followed. The sponsor logged completion for 30 April 2024. Primary outcome, as filed: Effects of Semaglutide on Quantity of Abdominal Fat (Total, Subcutaneous, Visceral) at Week 32 Compared to Baseline. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: ACTIVE_NOT_RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Case Western Reserve University
Sponsor type: Other
Enrollment: 108
Started: 2019-05-16
Primary completion: 2024-04-30 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Effects of Semaglutide on Quantity of Abdominal Fat (Total, Subcutaneous, Visceral) at Week 32 Compared to Baseline

Conditions studied

HIV/AIDS · Lipohypertrophy · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.